Olaparib to Change Practice in mCRPC.
Olaparib can be effective in patients with metastatic castration-resistant prostate cancer who have homologous recombination repair gene alterations. In the phase III PROfound trial, the drug extended median radiographic progression-free survival and increased objective response rate in patients with BRCA 1/2 and ATM mutations, compared with enzalutamide or abiraterone plus prednisone.